Rocket Pharmaceuticals sold its rare disease pediatric priority review voucher for $180 million to support its pipeline, which includes a gene therapy for Danon disease, a condition with no FDA-approved treatments. The sale reflects increasing demand for such vouchers, with prices rising from around $100 million in previous years.
The sale of Rocket Pharmaceuticals' rare disease pediatric priority review voucher for $180 million underscores the increasing value of these regulatory fast passes, with prices rising from around $100 million to $180 million recently. This trend signals a lucrative opportunity for biotech companies developing therapies for rare diseases, as such vouchers can be strategically sold to large pharmaceutical companies to support further pipeline development, such as Rocket's RP-A501 gene therapy for Danon disease.